Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 58.7% in December

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 31,500 shares, a decrease of 58.7% from the December 15th total of 76,200 shares. Based on an average daily trading volume, of 787,700 shares, the short-interest ratio is currently 0.0 days.

Astellas Pharma Stock Up 0.6 %

Shares of ALPMY stock traded up $0.06 during mid-day trading on Tuesday, hitting $9.54. The company's stock had a trading volume of 487,929 shares, compared to its average volume of 305,566. The stock has a market cap of $17.26 billion, a price-to-earnings ratio of 45.43 and a beta of 0.34. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.72 and a current ratio of 0.90. Astellas Pharma has a 52-week low of $9.15 and a 52-week high of $13.14. The business has a 50-day moving average price of $10.14 and a 200 day moving average price of $11.02.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.33%. The business had revenue of $3.11 billion for the quarter. Research analysts predict that Astellas Pharma will post 0.61 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.